Evidence map›Paper›PMID 34565928›Full record

ArticleCytology and genetics2021

Relationship between the Prevalence of ACE1 I/D Polymorphism Genotype II and Covid-19 Morbidity, Mortality in Ukraine and in Some Europe Countries.

L A Livshits, T A Harashchenko, T R Umanets, D S Krasnienkov, O V Gorodna, Vl V Podolskiy, T M Kaminska, V F Lapshyn, V V Podolskiy, Yu G Antipkin

Open access · bronzeAbstract read
In one paragraph

Article in Cytology and genetics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. The I/D variant of theFuture science OA · 2025
    Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

L A LivshitsInstitute of Molecular Biology and Genetics National Academy of Sciences of Ukraine, 03143 Kyiv, Ukraine.
T A HarashchenkoState Institution "Institute of Pediatrics, Obstetrics and Gynecology named after Academician O.M. Lukyanova, National Academy of Medical Sciences of Ukraine", 04050 Kyiv, Ukraine.
T R UmanetsState Institution "Institute of Pediatrics, Obstetrics and Gynecology named after Academician O.M. Lukyanova, National Academy of Medical Sciences of Ukraine", 04050 Kyiv, Ukraine.
D S KrasnienkovState Institution "Institute of Gerontology named after Dmitry F. Chebotarev, National Academy of Medical Sciences of Ukraine", 04114 Kyiv, Ukraine.
O V GorodnaInstitute of Molecular Biology and Genetics National Academy of Sciences of Ukraine, 03143 Kyiv, Ukraine.
Vl V PodolskiyState Institution "Institute of Pediatrics, Obstetrics and Gynecology named after Academician O.M. Lukyanova, National Academy of Medical Sciences of Ukraine", 04050 Kyiv, Ukraine.
T M KaminskaKyiv City Children's Clinical Hospital of Infectious Diseases, 04119 Kyiv, Ukraine.
V F LapshynState Institution "Institute of Pediatrics, Obstetrics and Gynecology named after Academician O.M. Lukyanova, National Academy of Medical Sciences of Ukraine", 04050 Kyiv, Ukraine.
V V PodolskiyState Institution "Institute of Pediatrics, Obstetrics and Gynecology named after Academician O.M. Lukyanova, National Academy of Medical Sciences of Ukraine", 04050 Kyiv, Ukraine.
Yu G AntipkinState Institution "Institute of Pediatrics, Obstetrics and Gynecology named after Academician O.M. Lukyanova, National Academy of Medical Sciences of Ukraine", 04050 Kyiv, Ukraine.
Institute of Pediatrics, Obstetrics, and Gynecology named after acad. O.M. Lukyanova of the National Academy of Medical Sciences of Ukraine · UAInstitute of Molecular Biology and Genetics · UAKyiv City Clinical Oncology Center · UANational Academy of Medical Sciences of Ukraine · UANational Academy of Sciences of Ukraine · UA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Coronavirus disease (COVID-19), which was first recorded in China in December 2019, quickly spread to other countries and in a short period of time, the local outbreak escalated into a pandemic. There are significantly more cases of COVID-19 morbidity and mortality in European countries than in East Asia, where the disease was first detected. Such population differences are unique, especially for SARS-CoV-2 and are due to both socio-behavioral differences and features of the gene pool of the population of different countries. For infectious diseases, such as COVID-19, an important point is the genetic characteristics of individuals, which can determine its resistance or susceptibility to infection. Therefore, studies of the factors of hereditary predisposition to SARS-CoV-2 infection, as well as severity and mortality are extremely relevant. After genotyping among the healthy population of Ukraine and collecting relevant data from some European countries, we determined the correlation between morbidity, mortality from COVID-19 and the prevalence of genotype II (ACE1, I/D polymorphism) in the populations of Ukraine and several European countries. There was a negative correlation between the carrier of genotype II and susceptibility to SARS-CoV-2 infection per one million population (

Identifiers

PMID34565928
PMCPMC8450713
OpenAlexW3200210881

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.